{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:26:15Z","timestamp":1774959975112,"version":"3.50.1"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Erythema multiforme (EM) is an immune-mediated condition marked by recurrent targetoid lesions, occasionally involving mucous membranes. Chronic or treatment-resistant cases can be difficult to manage, with limited options when standard therapies fail. We report a 37-year-old man with long-standing, refractory EM who experienced frequent flares despite trials of corticosteroids, antivirals, dapsone, methotrexate, hydroxychloroquine, ciclosporin, thalidomide and intravenous immunoglobulin. After receiving two rituximab infusions, the patient achieved complete remission, and remained symptom-free and off systemic treatment at the 5-year follow-up. This case highlights the potential role of rituximab in managing severe, treatment-resistant EM and suggests that B-cell-targeted therapy may offer long-term disease control when conventional therapies are ineffective.<\/jats:p>","DOI":"10.1093\/skinhd\/vzaf105","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:01:12Z","timestamp":1765630872000},"page":"168-170","source":"Crossref","is-referenced-by-count":0,"title":["Breaking the cycle: successful long-term remission of chronic erythema multiforme with rituximab therapy"],"prefix":"10.1093","volume":"6","author":[{"given":"Hira","family":"Ghani","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Warren Alpert Medical School of Brown University , Providence, RI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaim","family":"Haq","sequence":"additional","affiliation":[{"name":"The Warren Alpert Medical School of Brown University , Providence, RI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-6609","authenticated-orcid":false,"given":"Isabella","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Rutgers Robert Wood Johnson School of Medicine , Somerset, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Reginato","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, The Warren Alpert Medical School of Brown University , Providence, RI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrar A","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Warren Alpert Medical School of Brown University , Providence, RI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2026033107430837600_vzaf105-B1","first-page":"1","volume-title":"StatPearls","author":"Hafsi","year":"2024"},{"key":"2026033107430837600_vzaf105-B2","first-page":"82","article-title":"Erythema multiforme: recognition and management","volume":"100","author":"Trayes","year":"2019","journal-title":"Am Fam Physician"},{"key":"2026033107430837600_vzaf105-B3","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/jdv.13313","article-title":"Rituximab, a new treatment for difficult-to-treat chronic erythema multiforme major? Five cases","volume":"30","author":"Hirsch","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026033107430837600_vzaf105-B4","doi-asserted-by":"crossref","first-page":"e12449","DOI":"10.1111\/dth.12449","article-title":"Treatment of \u00adantiviral-resistant recurrent erythema multiforme with dapsone","volume":"30","author":"Oak","year":"2017","journal-title":"Dermatol Ther"},{"key":"2026033107430837600_vzaf105-B5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/medicina57090921","article-title":"Recent updates in the treatment of erythema multiforme","volume":"57","author":"Soares","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2026033107430837600_vzaf105-B6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/2\/168\/66326656\/vzaf105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/2\/168\/66326656\/vzaf105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:43:13Z","timestamp":1774957393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/2\/168\/8418332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":6,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzaf105","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,9]]}}}